Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimer's Disease.
Fiche du document
2020
- doi: 10.3389/fnins.2020.00563
- issn: 1662-453X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3389/fnins.2020.00563
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32612499
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1662-4548
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E8D14572B9A96
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Lariam (Trademark) Mephaquin (Trademark) Mephaquine (Trademark)Citer ce document
M. Droguerre et al., « Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimer's Disease. », Serveur académique Lausannois, ID : 10.3389/fnins.2020.00563
Métriques
Partage / Export
Résumé
Donepezil (DPZ) is an acetylcholinesterase inhibitor used in Alzheimer's disease to restore cognitive functions but is endowed with limited efficacy. Recent studies pointed out the implication of astroglial networks in cognitive processes, notably via astrocyte connexins (Cxs), proteins involved in gap junction intercellular communications. Hence, we investigated the impact on cognition of pharmacological or genetic modulations of those astrocyte Cxs during DPZ challenge in two rodent models of Alzheimer's disease-like memory deficits. We demonstrated that the Cx modulator mefloquine (MEF) significantly enhanced the procognitive effect of DPZ in both models. In parallel, we determined that MEF potentiated DPZ-induced release of acetylcholine in hippocampus. Finally, local genetic silencing of astrocyte Cxs in the hippocampus was also found to enhance the procognitive effect of DPZ, pointing out the importance of Cx-dependent astrocyte networks in memory processes.